ketoconazole has been researched along with Adverse Drug Event in 13 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "Ketoconazole (KT) is a broad-spectrum antifungal agent whose pharmacological activity is based on the capability to interfere with steroid biosynthesis through an interaction with fungal cytochrome P-450 enzymes and thereby avoiding the formation of fungal walls." | 1.35 | Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses. ( Amaral, VC; Nunes, GP, 2009) |
| " Collections of individual case safety reports (ICSRs) related to suspected ADR incidents in clinical practice have proven to be very useful in post-marketing surveillance for pairwise drug--ADR associations, but have yet to reach their full potential for drug-drug interaction surveillance." | 1.35 | A statistical methodology for drug-drug interaction surveillance. ( Bate, A; Edwards, IR; Norén, GN; Sundberg, R, 2008) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Machiels, JP | 1 |
| Staddon, A | 1 |
| Herremans, C | 1 |
| Keung, C | 1 |
| Bernard, A | 1 |
| Phelps, C | 1 |
| Khokhar, NZ | 1 |
| Knoblauch, R | 1 |
| Parekh, TV | 1 |
| Dirix, L | 1 |
| Sharma, S | 1 |
| Amaral, VC | 1 |
| Nunes, GP | 1 |
| Jones, HM | 1 |
| Dickins, M | 1 |
| Youdim, K | 1 |
| Gosset, JR | 1 |
| Attkins, NJ | 1 |
| Hay, TL | 1 |
| Gurrell, IK | 1 |
| Logan, YR | 1 |
| Bungay, PJ | 1 |
| Jones, BC | 1 |
| Gardner, IB | 1 |
| Sui, Q | 1 |
| Wang, B | 1 |
| Zhao, W | 1 |
| Huang, J | 1 |
| Yu, G | 1 |
| Deng, S | 1 |
| Qiu, Z | 1 |
| Lu, S | 1 |
| Norén, GN | 1 |
| Sundberg, R | 1 |
| Bate, A | 1 |
| Edwards, IR | 1 |
| Ciummo, PE | 1 |
| Katz, NL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Multicenter Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies[NCT01267084] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| An Open-Label, Multicenter Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Subjects With Advanced Malignancies[NCT01273480] | Phase 1 | 12 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ketoconazole and Adverse Drug Event
| Article | Year |
|---|---|
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Dr | 2014 |
12 other studies available for ketoconazole and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Prednisone reduces ketoconazole-induced skeletal defects in rat fetuses.
Topics: Abnormalities, Drug-Induced; Animals; Bone and Bones; Dose-Response Relationship, Drug; Drinking; Dr | 2009 |
Application of PBPK modelling in drug discovery and development at Pfizer.
Topics: Drug Discovery; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Ketocona | 2012 |
Identification of priority pharmaceuticals in the water environment of China.
Topics: Anti-Bacterial Agents; Cephalexin; China; Diclofenac; Drug Utilization; Drug-Related Side Effects an | 2012 |
A statistical methodology for drug-drug interaction surveillance.
Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Contraceptives, Or | 2008 |
Interactions and drug-metabolizing enzymes.
Topics: Adolescent; Adult; Anti-Allergic Agents; Antidepressive Agents, Second-Generation; Antifungal Agents | 1995 |